TD Cowen initiated coverage of Ceribell (CBLL) with a Buy rating and $31 price target The company’s technology tackles the limitations of conventional EEG in the acute care setting, the analyst tells investors in a research note. The firm says this offers workflow benefits to physicians and staff and economic benefits to hospitals.
Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
The Fly
Ceribell initiated with a Buy at TD Cowen
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App